Formulary Adherence Checklist for NICE Technology Appraisals About Medicines

Milton Keynes Health Economy

Developed for the NHS by: **East and South East England Specialist Pharmacy Services**

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. Version 20 January 2018
All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.

Technology appraisal (TA) Titles are hyperlinks to full guidance	***Date of TA Release***	***Availability of medicine for NHS patients with this medical condition, as indicated by NICE***	***Adherence of local formulary to NICE***				
			Yes *(mark 'x' if applicable)*	***N/A*** *(mark 'x' if applicable)*	***Date of local decision*** *(DD/MM/YY)*	***Time to implement*** *(days)*	***Notes*** *(e.g. rationale, method of making available)*
2017/2018							
Golimumab for treating non-radiographic axial spondyloarthritis (TA497)	10/01/2018	**Golimumab (Simponi®)** is recommended, within its marketing authorisation, as an option for treating severe non-radiographic axial spondyloarthritis in adults whose disease has responded inadequately to, or who cannot tolerate, nonsteroidal anti-inflammatory drugs.	x		24/01/2018	14	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)	20/12/2017	**Ribociclib (Kisqali)**, with an aromatase inhibitor, is recommended within its marketing authorisation, as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer as initial endocrine-based therapy in adults	x		24/01/2018	35	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)	20/12/2017	**Palbociclib (Ibrance)**, with an aromatase inhibitor, is recommended within its marketing authorisation, as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer as initial endocrine-based therapy in adults	x		24/01/2018	35	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Naltrexone–bupropion for managing overweight and obesity (TA494)	12/12/2017	**Naltrexone–bupropion (Mysimba)** is not recommended within its marketing authorisation for managing overweight and obesity in adults alongside a reduced-calorie diet and increased physical activity	x		24/01/2018	43	Not recommended
Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)	06/12/2017	**Cladribine tablets (Mavenclad)** are recommended as an option for treating highly active multiple sclerosis in adults	x		24/01/2018	49	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements

Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)	06/12/2017	**Atezolizumab (Tecentriq)** is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable	x		24/01/2018	49	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)	22/11/2017	**Ibrutinib (Imbruvica)** is recommended for use in the Cancer Drugs Fund as an option for treating Waldenstrom's macroglobulinaemia in adults who have had at least 1 prior therapy	x		24/01/2018	63	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)	22/11/2017	**Nivolumab (Opdivo)** is recommended for use within the Cancer Drugs Fund as an option for treating squamous cell carcinoma of the head and neck in adults whose disease has progressed on platinum-based chemotherapy	x		24/01/2018	63	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Vismodegib for treating basal cell carcinoma (TA489)	22/11/2017	**Vismodegib (Erivedge)** is not recommended within its marketing authorisation for treating symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that is inappropriate for surgery or radiotherapy	x		24/01/2018	63	Not recommended
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)	15/11/2017	**Regorafenib (Stivarga)** is recommended as an option for treating unresectable or metastatic gastrointestinal stromal tumours in adults whose disease has progressed on, or who are intolerant to, prior treatment with imatinib and sunitinib	x		24/01/2018	70	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Venetoclax for treating chronic lymphocytic leukaemia (TA487)	01/10/2017	**Venetoclax (Venclyxto®)** is recommended for use within the Cancer Drugs Fund, within its marketing authorisation, as an option for treating chronic lymphocytic leukaemia	x		29/11/2017	59	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Aflibercept for treating choroidal neovascularisation (TA486)	01/10/2017	**Aflibercept (Eylea®)** is recommended, within its marketing authorisation, as an option for treating visual impairment because of myopic choroidal neovascularisation in adults	x		29/11/2017	59	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Sarilumab for moderate to severe rheumatoid arthritis (TA485)	01/10/2017	**Sarilumab (Kevzara®)** with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying anti-rheumatic drugs (DMARDs)	x		29/11/2017	59	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)	01/10/2017	**Nivolumab (Opdivo®)** is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic non-squamous non-small-cell lung cancer in adults after chemotherapy	x		29/11/2017	59	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements

Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)	01/10/2017	**Nivolumab (Opdivo®)** is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic squamous non-small-cell lung cancer in adults after chemotherapy	x		29/11/2017	59	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Immunosuppressive therapy for kidney transplant in children and young people (TA482)	01/10/2017	Immunosuppressive therapy for kidney transplant in children and young people	x		29/11/2017	59	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Immunosuppressive therapy for kidney transplant in adults (TA481)	01/10/2017	Immunosuppressive therapy for kidney transplant in adults	x		29/11/2017	59	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Tofacitinib for moderate to severe rheumatoid arthritis (TA480)	01/10/2017	**Tofacitinib (Xeljanz®)** is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying anti-rheumatic drugs (DMARDs)	x		29/11/2017	59	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Reslizumab for treating severe eosinophilic asthma (TA479)	01/10/2017	**Reslizumab (Cinqaero®)** is recommended as an option for the treatment of severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids plus another drug	x		29/11/2017	59	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)	01/10/2017	**Brentuximab vedotin (Adcetris®)** is recommended as an option for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults	x		29/11/2017	59	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)	01/10/2017	**Autologous chondrocyte implantation (ACI) ChondroCelect®** is recommended as an option for treating symptomatic articular cartilage defects of the knee	x		29/11/2017	59	NICE Appraisal N/A at MK
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)	06/09/2017	**Paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) with gemcitabine** is recommended as an option for untreated metastatic adenocarcinoma of the pancreas in adults	x		27/09/2017	21	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)	06/09/2017	**Dimethyl fumarate** is recommended as an option for treating plaque psoriasis in adults	x		29/11/2017	84	Confirmed place in therapy with dermatologists. CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements.
Sorafenib for treating advanced hepatocellular carcinoma (TA474)	06/09/2017	**Sorafenib** is recommended as an option for treating advanced hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment	x		27/09/2017	21	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)	31/08/2017	**Cetuximab in combination with platinum-based chemotherapy** is recommended as an option for treating recurrent or metastatic squamous cell cancer of the head and neck in adults	x		27/09/2017	27	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements.

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)	30/08/2017	**Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance** is recommended for use within the Cancer Drugs Fund as an option for treating adults with follicular lymphoma that did not respond or progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen	x		27/09/2017	28	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)	30/08/2017	**Eluxadoline** is recommended as an option for treating irritable bowel syndrome with diarrhoea in adults	x		27/09/2017	28	Approved for addition to the formulary and to be used in line with NICE guidance with Secondary Care Initiation and stabilisation including one month review.
Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) (TA470)	23/08/2017	**Ofatumumab with chemotherapy** - was unable to make a recommendation about the use in the NHS of ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia because no evidence submission was received from Novartis Pharmaceuticals UK	x		27/09/2017	35	Terminated Appraisal by NICE
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) (TA469)	23/08/2017	NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence submission was received	x		27/09/2017	35	Terminated Appraisal by NICE
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) (TA468)	23/08/2017	Methylnaltrexone bromide - was unable to make a recommendation about the use in the NHS of methylnaltrexone bromide for treating opioid-induced constipation because no evidence submission was received from Swedish Orphan Biovitrum Ltd	x		27/09/2017	35	Terminated Appraisal by NICE
Holoclar for treating limbal stem cell deficiency after eye burns (TA467)	16/08/2017	**Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells)** is recommended as an option in people with moderate to severe limbal stem cell deficiency after eye burns	x		27/09/2017	42	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Baricitinib for moderate to severe rheumatoid arthritis (TA466)	09/08/2017	**Baricitinib, with methotrexate** is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs),	x		27/09/2017	49	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465)	09/08/2017	**Olaratumab, in combination with doxorubicin**, is recommended for use within the Cancer Drugs Fund as an option for advanced soft tissue sarcoma in adults	x		27/09/2017	49	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Bisphosphonates for treating osteoporosis (TA464)	09/08/2017	**Oral bisphosphonates** (alendronic acid, ibandronic acid and risedronate sodium) are recommended as options for treating osteoporosis in adults	x		27/09/2017	49	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements

Cabozantinib for previously treated advanced renal cell carcinoma (TA463)	09/08/2017	**Cabozantinib** is recommended, within its marketing authorisation, as an option for treating advanced renal cell carcinoma in adults after vascular endothelial growth factor (VEGF)-targeted therapy	x		27/09/2017	49	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)	26/07/2017	**Nivolumab** is recommended, within its marketing authorisation, as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults after autologous stem cell transplant and treatment with brentuximab vedotin, when the company provides nivolumab with the discount agreed in the patient access scheme.	x		27/09/2017	63	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Roflumilast for treating chronic obstructive pulmonary disease (TA461)	26/07/2017	**Roflumilast**, as an add-on to bronchodilator therapy, is recommended as an option for treating severe chronic obstructive pulmonary disease in adults with chronic bronchitis	x		27/09/2017	63	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)	26/07/2017	**Adalimumab** is recommended as an option for treating non-infectious uveitis in the posterior segment of the eye in adults with inadequate response to corticosteroids. Dexamethasone (Ozurdex®) intravitreal implant is recommended as an option for treating non-infectious uveitis in the posterior segment of the eye in adults	x		27/09/2017	63	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)	26/07/2017	**Collagenase clostridium histolyticum** for people who meet the inclusion criteria for the ongoing clinical trial (HTA-15/102/04), comparing collagenase clostridium histolyticum (CCH) with limited fasciectomy, are encouraged to participate in the study. For people not taking part in the ongoing clinical trial, CCH is recommended as an option for treating Dupuytren's contracture with a palpable cord in adults	x		27/09/2017	63	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)	19/07/2017	**Trastuzumab emtansine** is recommended, within its marketing authorisation, as an option for treating human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who previously received trastuzumab and a taxane, separately or in combination.	x		27/09/2017	70	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Carfilzomib for previously treated multiple myeloma (TA457)	19/07/2017	**Carfilzomib in combination with dexamethasone** is recommended as an option for treating multiple myeloma in adults	x		27/09/2017	70	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)	12/07/2017	**Ustekinumab** is recommended, within its marketing authorisation, as an option for treating moderately to severely active Crohn's disease, that is, for adults who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-alpha inhibitor or have medical contraindications to such therapies.	x		27/09/2017	77	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)	12/07/2017	**Adalimumab, Etanercept and Ustekinumab** is recommended as an option for treating plaque psoriasis in children and young people aged 4 years or older	x		27/09/2017	77	Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA454)	05/07/2017	**Daratumumab** - was unable to make a recommendation about the use in the NHS of daratumumab, with lenalidomide and dexamethasone, for treating relapsed or refractory multiple myeloma because no evidence submission was received from Janssen-Cilag	x		26/07/2017	21	Terminated Appraisal by NICE
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) (TA453)	05/07/2017	**Bortezomib** - was unable to make a recommendation about the use in the NHS of bortezomib for treating multiple myeloma after second or subsequent relapse because no evidence submission was received from Janssen-Cilag	x		26/07/2017	21	Terminated Appraisal by NICE
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) (TA452)	05/07/2017	**Ibrutinib** - was unable to make a recommendation about the use in the NHS of ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation because no evidence submission was received from Janssen–Cilag	x		26/07/2017	21	Terminated Appraisal by NICE
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)	28/06/2017	**Ponatinib (Iclusig)** is recommended, within its marketing authorisation, as an option for treating chronic-, accelerated- or blast-phase chronic myeloid leukaemia in adults	x		26/07/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)	28/06/2017	**Blinatumomab (Blincyto)** is recommended within its marketing authorisation as an option for treating Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults, only if the company provides it with the discount agreed in the patient access scheme.	x		26/07/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)	28/06/2017	**Everolimus (Afinitor) and Sunitinib (Sutent)** are recommended, within their marketing authorisations, as options for treating well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease.	x		26/07/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements

Etelcalcetide for treating secondary hyperparathyroidism (TA448)	28/06/2017	**Etelcalcetide (Parsabiv)** is recommended as an option for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis	x		26/07/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)	28/06/2017	**Pembrolizumab (Keytruda)** is recommended for use within the Cancer Drugs Fund as an option for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults	x		26/07/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)	28/06/2017	**Brentuximab vedotin (Adcetris)** is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults	x		26/07/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)	24/05/2017	**Certolizumab pegol (Cimzia) alone, or in combination with methotrexate** is recommended as an option for treating active psoriatic arthritis in adults	x		26/07/2017	63	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements.
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA444)	22/03/2017	**Tenofovir alafenamide** - was unable to make a recommendation about the use in the NHS of afatinib for treating locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy because no evidence submission was received from Boehringer Ingelheim.	x		24/05/2017	63	Terminated Appraisal by NICE
Obeticholic acid for treating primary biliary cholangitis (TA443)	26/04/2017	**Obeticholic acid (Ocaliva)** is recommended, within its marketing authorisation, as an option for treating primary biliary cholangitis in combination with ursodeoxycholic acid for people whose disease has responded inadequately to ursodeoxycholic acid or as monotherapy for people who cannot tolerate ursodeoxycholic acid. Obeticholic acid is recommended only if the company provides it with the discount agreed in the patient access scheme.	x		24/05/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Ixekizumab for treating moderate to severe plaque psoriasis (TA442)	26/04/2017	Ixekizumab (Taltz) is recommended as an option for treating plaque psoriasis in adults	x		24/05/2017	28	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements.
Daclizumab for treating relapsing–remitting multiple sclerosis (TA441)	26/04/2017	**Daclizumab (Zinbryta)** is recommended as an option for treating multiple sclerosis in adults	x		24/05/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)	26/04/2017	**Pegylated liposomal irinotecan (Onivyde)**, in combination with 5-fluorouracil and leucovorin, is not recommended, within its marketing authorisation, for treating metastatic adenocarcinoma of the pancreas in adults whose disease has progressed after gemcitabine-based therapy.	x		24/05/2017	28	Not recommended
			58	0			

			% "Yes"	% "N/A"	_	Average implement time (days)	
Adherence statistics for 2017-18			100%	0%		**47**	